Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 10434154 Composition for treating prostate cancer (PCa)

Patent 10434154 was granted and assigned to CureVac on October, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
CureVac
CureVac
0
Date Filed
June 30, 2016
0
Date of Patent
October 8, 2019
0
Patent Applicant
CureVac
CureVac
0
Patent Application Number
15198456
0
Patent Citations Received
‌
US Patent 12109275 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded protein
0
‌
US Patent 11786590 Rotavirus vaccines
‌
US Patent 11834651 Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
0
‌
US Patent 11865084 MERS coronavirus vaccine
0
‌
US Patent 11965000 Respiratory syncytial virus (RSV) vaccine
0
‌
US Patent 12083190 Rabies vaccine
0
‌
US Patent 11661634 Method for producing RNA
0
‌
US Patent 11667910 Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
0
‌
US Patent 11760992 Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
‌
US Patent 11761009 Artificial nucleic acid molecules for improved protein expression
Patent Inventor Names
Ingmar Hoerr
0
Jochen Probst
0
Thomas Lander
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
10434154
0
Patent Primary Examiner
‌
Jennifer Dunston
0

Find more entities like US Patent 10434154 Composition for treating prostate cancer (PCa)

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.